Immunovant rises as attention swings back to IMVT-1402 after TED readout
Immunovant shares are higher as investors refocus on the company’s next-generation FcRn candidate IMVT-1402 after the April 2 update on batoclimab in thyroid eye disease. The move also follows fresh sell-side framing that IMVT-1402 could support multi-billion-dollar peak sales, even as some analysts urge patience for upcoming data.
1) What’s moving the stock
Immunovant (IMVT) is trading up about 3.6% to $25.78 as biotech flows rotate back into names with clear next-step catalysts and investors re-center the story on IMVT-1402, the company’s next-generation FcRn blocker. The rebound comes in the wake of Immunovant’s April 2 update in which batoclimab’s Phase 3 thyroid eye disease (TED) program did not meet its primary endpoint, while the company emphasized it remains focused on rapidly advancing IMVT-1402 across multiple indications. (biospace.com)
2) The overhang investors are digesting
On April 2, Immunovant said both Phase 3 “GO” studies of batoclimab in TED failed to meet the prespecified Week 24 primary endpoint (≥2mm proptosis responder rate) after 12 weeks of high-dose followed by 12 weeks of low-dose dosing; the company reported safety consistent with prior findings and no new safety signals. The company also highlighted a pattern of greater proptosis improvement after the initial high-dose period than after the later low-dose period, reinforcing investor focus on whether deeper IgG suppression—and potentially a different profile—could matter in future FcRn programs. (biospace.com)
3) Why sentiment can still firm up from here
Despite the TED disappointment for batoclimab, Immunovant’s near- to mid-term equity narrative is increasingly tied to IMVT-1402 and the breadth of potential indications rather than a single TED launch path. In recent sell-side initiation, Jefferies started coverage with a Hold rating and a $20 price target, arguing IMVT-1402 could still be worth significant value with potential peak sales around $3 billion, but that investors may need to wait for more meaningful readouts—an outlook that can still support tactical buying on down days as positions reset. (tipranks.com)
4) What to watch next
Near-term trading is likely to remain sensitive to (1) any clarity on batoclimab’s future development strategy with partners, and (2) cadence and quality of IMVT-1402 clinical updates across prioritized autoimmune indications. Immunovant has stated topline data from potentially registrational studies of IMVT-1402 in Graves’ disease are expected in calendar 2027, setting expectations that 2026 upside may be driven more by interim clinical execution updates, pipeline de-risking signals, and analyst positioning than by pivotal efficacy readouts. (biospace.com)